ESTRO 2025 - Abstract Book

S1697

Clinical - Sarcoma & skin cancer & malignant melanoma

ESTRO 2025

Six patients (10%) developed acute grade 3 toxicities including anaemia (n=3), anorexia (n=2), nausea and vomiting (n=1), and oropharyngeal mucositis (n=1). Five patients (8%) developed late grade 3 toxicities including duodenal haemorrhage, anorexia, lower back pain associated with a sacral insufficiency fracture, and progressive sphincter dysfunction and lower limb weakness due to worsening pre-existing sacral plexopathy. Conclusion: These data indicate that moderately hypofractionated definitive radiotherapy using a simultaneous integrated boost technique can be delivered to inoperable non-extremity sarcomas with acceptable toxicity and encouraging early local control rates. This represents an attractive alternative radical treatment option in patients who are ineligible for surgery. Ongoing investigation with a prospective study in this context is warranted.

Keywords: Hypofractionated, definitive

References: 1. Roohani S, Ehret F, Kobus M et al. Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review. Radiat Oncol. 2022; 17: 159. 2. Haas RL, Floot BGJ, Scholten AN et al. Cellular radiosensitivity of soft tissue sarcoma. Radiat Res. 2021; 196: 23-30.